New Assistant Controller opportunity with a clinical-stage, pre-IPO Biotech in Boston. Send us your resume! #TheManningWay #AssistantController #PreIPO #Biotech
Manning Personnel Group, Inc.’s Post
More Relevant Posts
-
Calling all Pre-seed and Seed stage Biotech companies in the UK and Boston 🚨 We understand that you want to build an amazing company whilst going about your mission to change the medical landscape - but with delivering science and raising money taking priority and finances being allocated elsewhere, it can be difficult to prioritise Culture and People as part of your business' overall strategy. We want to help 💡 so we're offering a free 6 month advisory programme for a limited time only, during which our highly-skilled People Partners will work with you to: 👉🏼 Define the Culture you're intending to create 👉🏼 Drive that Culture, along with engagement, retention and development initiatives for your people 👉🏼 Create a compelling Mission, Purpose and Vision for the long term 👉🏼 Review your hiring processes, job descriptions and proposition to help you attract and secure amazing people 👉🏼 Put in place the systems and processes that will drive your business and save you time and money We'll provide expert advice, introductions, templates, ideas and a whole lot more during a timeframe of 1-2 hours each month over a 6 month period. For more information or to take advantage of this free support, email tom@singular-biotech.com or contact us via our website https://lnkd.in/ebpV4rUE #biotech #techbio #lifesciences #biotechnology #startup #drugdiscovery #drugdevelopment #culture #people
To view or add a comment, sign in
-
HiRO's CEO Karen Chu discusses our role in suporting biotechs with limited resources. We offer flexible support, from staffing specialized roles to complete project outsourcing, helping to transform innovative ideas into clinical realities. Learn in this video how HiRO is committed to nurturing biotech success. #HiRO #BiotechInnovation #ClinicalResearchSupport #HealthcareSolutions #ResourceOptimization
To view or add a comment, sign in
-
Financial Adviser | BiotechAdviser.com | Helping Biotech, Pharma, and Life Science Executives/Professionals with their Personal Financial Planning
Let's 𝐚𝐝𝐝𝐫𝐞𝐬𝐬 𝐜𝐨𝐦𝐦𝐨𝐧 𝐩𝐚𝐭𝐭𝐞𝐫𝐧𝐬 𝐰𝐞 𝐞𝐧𝐜𝐨𝐮𝐧𝐭𝐞𝐫 𝐰𝐢𝐭𝐡 𝐨𝐮𝐫 𝐁𝐢𝐨𝐭𝐞𝐜𝐡 𝐚𝐧𝐝 𝐏𝐡𝐚𝐫𝐦𝐚 𝐂𝐥𝐢𝐞𝐧𝐭𝐬 and how we approach them: 𝐏𝐚𝐭𝐭𝐞𝐫𝐧: One-Size-Fits-All Financial Planning for Life Science Executives and Professionals: 𝐏𝐨𝐭𝐞𝐧𝐭𝐢𝐚𝐥 𝐒𝐨𝐥𝐮𝐭𝐢𝐨𝐧: We understand that professionals in industry have unique financial planning needs. This could involve managing equity compensation, understanding benefits, navigating IPOS or acquisitions, negotiations, transitions from academia to industry, consulting, and more. *Basic and siloed investment planning may not always cover the depth of financial planning required by Biotech, Pharma, and Life Sciences Executives and Professionals.* Our experienced team focuses in working with Biotech, Pharma, and Life Science Professionals and Executives on their personal financial planning. We have a combined 20 years of experience working in Life Sciences and I also happen to be a Type 1 diabetic, so my interest in the Life Sciences ecosystem is personal. We're always happy to chat and see if our two worlds are a fit. #biotech #pharma #lifesciences #biotechnology #pharmaceuticals *this may or may not be accurate depending on your situation
To view or add a comment, sign in
-
Are you are a Phase III company and haven’t begun full scale commercialization build out? We can get you there – quickly and cost effectively. As a Phase III company, the commercialization focus should be on developing the Commercial & Medical Affairs “basecamp” including foundational investments in developing the “Commercialization Roadmap” (36 months prelaunch & launch year), establishing Medical Affairs, and initiating critical long timeline commercial imperatives. I'm Russ Belden, the founder & CEO of Bridge. If you don’t have the right Commercial leadership in place, are uncertain of your commercialization alternatives or, what it takes to commercialize successfully, give me a call and we’ll get your company on the path to commercial success. Russ Belden Bridge: Founder & CEO russ@bridge1.net www.bridge1.net 415-307-0774 Danville, CA At Bridge, we leverage our 36 years of biotech commercialization expertise from the early days at Genentech and 120 companies thereafter in providing the right level of commercial leadership at the right time. Our mission is making 1st time biotech CEO’s shine in the transition to a commercial company. #commercialization #PhaseIII #biotech #pharma #CEO #emergingbiotech #medicalaffairs
To view or add a comment, sign in
-
Condor and Danforth Advisors have joined forces to streamline clinical finance for biopharma companies. By integrating Condor’s software with Danforth’s clinical finance expertise, this collaboration enhances reporting accuracy, efficiency, and compliance. Quick wins include: 🚀 Accelerated Financial Close 🎯 Accurate Study Budgets 🤝 Unified Clinical, Business, and FP&A 🔒 Enhanced SOX Compliance Stay tuned for more updates! #clinicaltrials #biotech #clinicalfinance #Big4Bio #Big4
To view or add a comment, sign in
-
Enterprise Ireland’s new Seed and Venture Capital Scheme is set to inject fresh funding into the Irish start-up ecosystem, with a potential €175m in backing. This is fantastic news for innovation across all sectors, but particularly for the growing biopharma industry. As these start-ups gain the resources they need to scale, the demand for top talent will surge. For the biopharma industry, this means an increased need for specialised skills, particularly in areas like R&D, quality assurance, and regulatory affairs. Companies will be on the lookout for professionals who can drive their innovations forward and help them compete on a global stage. At Independent Solutions, we are ready to support this wave of growth. With our deep expertise in biopharma recruitment, we are here to connect these innovative start-ups with the skilled professionals they need to thrive. Whether you're a candidate looking for your next opportunity or a company ready to expand, we’re here to make the perfect match. Read more about this new scheme here: https://lnkd.in/ehPQyyG6 #IndependentSolutions #LifeSciences #BioPharma #Recruitment #Ireland #Innovation
To view or add a comment, sign in
-
Small cap health care and biotech companies have lagged the broader market in recent years, creating opportunities for skilled, active managers to close the valuation gap. Westfield Capital Management, manager of Harbor Capital Advisors, Inc.’s Small Cap Growth Fund, believes there are several compelling factors contributing to the attractiveness of small caps in health care, including: 🔷 Abatement of sustained elevated interest rates 🔷 Bottoming out of small cap valuations after a 2.5-year drawdown 🔷 An influx of cash to drive the next leg of innovation in biopharma 🔷 Acceleration of merger and acquisition activity as larger company patent cliff needs to become more acute 🔷 Buying opportunities created by weight-loss drug hysteria that contributed to carnage in high-quality, high-growth medtech stocks Check out an analysis of the opportunity: https://lnkd.in/ehgJxBeU
Small Cap Health Care Opportunity
To view or add a comment, sign in
-
Small cap health care and biotech companies have lagged the broader market in recent years, creating opportunities for skilled, active managers to close the valuation gap. Westfield Capital Management, manager of Harbor Capital Advisors, Inc.’s Small Cap Growth Fund, believes there are several compelling factors contributing to the attractiveness of small caps in health care, including: 🔷 Abatement of sustained elevated interest rates 🔷 Bottoming out of small cap valuations after a 2.5-year drawdown 🔷 An influx of cash to drive the next leg of innovation in biopharma 🔷 Acceleration of merger and acquisition activity as larger company patent cliff needs to become more acute 🔷 Buying opportunities created by weight-loss drug hysteria that contributed to carnage in high-quality, high-growth medtech stocks Check out an analysis of the opportunity: https://lnkd.in/e6fC5Rbw
Small Cap Health Care Opportunity
To view or add a comment, sign in
-
Small cap health care and biotech companies have lagged the broader market in recent years, creating opportunities for skilled, active managers to close the valuation gap. Westfield Capital Management, manager of Harbor Capital Advisors, Inc.’s Small Cap Growth Fund, believes there are several compelling factors contributing to the attractiveness of small caps in health care, including: 🔷 Abatement of sustained elevated interest rates 🔷 Bottoming out of small cap valuations after a 2.5-year drawdown 🔷 An influx of cash to drive the next leg of innovation in biopharma 🔷 Acceleration of merger and acquisition activity as larger company patent cliff needs to become more acute 🔷 Buying opportunities created by weight-loss drug hysteria that contributed to carnage in high-quality, high-growth medtech stocks Check out an analysis of the opportunity: https://lnkd.in/e6XKKNQg
Small Cap Health Care Opportunity
To view or add a comment, sign in
-
Small cap health care and biotech companies have lagged the broader market in recent years, creating opportunities for skilled, active managers to close the valuation gap. Westfield Capital Management, manager of Harbor Capital Advisors, Inc.’s Small Cap Growth Fund, believes there are several compelling factors contributing to the attractiveness of small caps in health care, including: 🔷 Abatement of sustained elevated interest rates 🔷 Bottoming out of small cap valuations after a 2.5-year drawdown 🔷 An influx of cash to drive the next leg of innovation in biopharma 🔷 Acceleration of merger and acquisition activity as larger company patent cliff needs to become more acute 🔷 Buying opportunities created by weight-loss drug hysteria that contributed to carnage in high-quality, high-growth medtech stocks Check out an analysis of the opportunity: https://lnkd.in/gSJsbRCW
Small Cap Health Care Opportunity
To view or add a comment, sign in
36,822 followers